Stock Market Reviews

APLS (Apellis Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on APLS (Apellis Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Is Apellis Pharmaceuticals’ FDA Win Just the Beginning?
  When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28. Today it sits at $19.96, down 31% over the past year. That disconnect reveals the gap between regulatory wins and commercial execution. The bull case starts with the label. EMPAVELI is the first ... Is Apellis Pharmaceuticals’ FDA Win Just the Beginning?
  Jan 17, 2026 - $APLS
• Sector Update: Health Care Stocks Mixed Premarket Friday
  Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR
  Jan 16, 2026 - $APLS
• Apellis Stock Crashes 23% in a Week: Here's What You Should Know
  APLS stock plunges 23% in a week after reporting $190 million in preliminary Q4 U.S. net product revenues, as weaker Syfovre sales and mixed Empaveli uptake disappoint investors.
  Jan 15, 2026 - $APLS
• Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS)
  Apellis Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining 2025 performance highlights and pipeline progress, including continued demand growth for SYFOVRE and market uptake for EMPAVELI in rare kidney diseases. The company also reported preliminary 2025 U.S. net product revenue of about US$689,000,000 and plans to seek approval for a SYFOVRE prefilled syringe in the first half of 2026, underscoring efforts to expand both its commercial...
  Jan 13, 2026 - $APLS
• A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion
  Apellis Pharmaceuticals (APLS) is back in focus after reporting preliminary 2025 U.S. net product revenue of about US$689 million, largely tied to SYFOVRE demand and the initial nephrology rollout of EMPAVELI. See our latest analysis for Apellis Pharmaceuticals. Despite interest around SYFOVRE demand and new EMPAVELI nephrology indications, Apellis’ recent share price return has been weak, with a 1-day share price decline of 15.02% and a year-to-date share price return decline of 10.29%. The...
  Jan 13, 2026 - $APLS
• Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference
  Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its near-term commercial priorities for Syfovre and Empaveli, discuss clinical and regulatory milestones, and preview longer-term pipeline ambitions built around complement factor
  Jan 12, 2026 - $APLS
• Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
  Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026Strong EMPAVELI® (pegcetacoplan) launch in C3G and primary IC-MPGN continues, with 267 new patient start forms in 2025; more than 5% market penetration following the first full quarter post-launchPivotal trials initiated for EMPAVELI in two additional nephrology indications, FSGS and D
  Jan 12, 2026 - $APLS
• JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won
  Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.
  Jan 12, 2026 - $APLS
• Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
  WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Phar
  Jan 5, 2026 - $APLS
• Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
  Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).
  Dec 12, 2025 - $APLS